Skip to main content
Full access
Letter to the Editor
Published Online: 1 January 2003

Dexamphetamine for Obsessive-Compulsive Disorder

Publication: American Journal of Psychiatry
To the Editor: Obsessive-compulsive disorder (OCD) may emerge with stimulant treatment for attention deficit hyperactivity disorder (ADHD). We report a case of OCD worsening with methylphenidate treatment but not with dexamphetamine. This adds to the sparse evidence for methylphenidate exacerbating obsessions and compulsions (13), suggests parallels with the emergence of tics in susceptible individuals when they are treated with stimulants, and may help illuminate genetic and neurochemical relationships between OCD and tic disorders.
Andy, an 11-year-old boy with ADHD diagnosed at age 5, was treated with methylphenidate. His overactivity, impulsivity, and attention improved, but anxiety symptoms emerged as the dose was increased to 40 mg/day. He started washing his hands excessively; this was accompanied by checking rituals, reassurance seeking, and emetophobia. OCD was diagnosed, and behavior therapy was initiated. For 1 year, Andy’s hyperactivity and impulsivity were well controlled with methylphenidate, but his obsessions and compulsions continued.
At his assessment in our service, Andy met DSM-IV criteria for OCD, and a cognitive behavior program was continued with some success. After 3 months, Andy still had significant OCD symptoms. Because his ADHD was quiescent, methylphenidate was withdrawn, as it is a potential anxiogenic agent. His response after 1 week was dramatic; Andy had reduced ritualization and anxiety. His hyperactivity and concentration were unaffected, but his parents found him more affectionate. This improvement lasted 3 weeks before Andy experienced a resurgence of hyperactivity, poor concentration, and attacks of rage. Risperidone, 1 mg/day, was added to his treatment and had some effect on his rage but no impact on his anxiety. His OCD symptoms remained in remission, so methylphenidate was gradually reintroduced. His OCD symptoms then returned, especially the reassurance seeking, hand washing, and fear of illness.
Dexamphetamine was substituted for methylphenidate and was gradually increased to 30 mg/day. The anxiety and ritualistic behavior lessened. After 6 weeks, there was still some generalized anxiety and a depressed mood, so citalopram, 10 mg/day, was added. This was associated with significant improvement in affective and anxiety symptoms, socialization, and school performance. These three medications—dexamphetamine, risperidone, and citalopram—have been maintained for Andy, who continues to improve.
Methylphenidate and dexamphetamine are often used interchangeably in ADHD treatment but have differing effects on dopaminergic and serotonergic metabolism. In complex comorbidity, subtle differences in metabolism and receptor sensitivity may require careful pharmacological choice. Dexamphetamine may be more suitable for ADHD with associated OCD (4). Recent case reports (5, 6) have implied that dexamphetamine improves OCD symptoms, further suggesting the need for more research into dopaminergic and serotonergic interactions in OCD (7).

References

1.
Kotsopoulos S, Spivak M: Obsessive-compulsive symptoms secondary to methylphenidate treatment (letter). Can J Psychiatry 2001; 46:89
2.
Kouris S: Methylphenidate-induced obsessive-compulsiveness (letter). J Am Acad Child Adolesc Psychiatry 1998; 37:135
3.
Koizumi HM: Obsessive-compulsive symptoms following stimulants (letter). Biol Psychiatry 1985; 20:1332-1333
4.
Joffe RT, Swinson RP, Levitt AJ: Acute psychostimulant challenge in primary obsessive-compulsive disorder. J Clin Psychopharmacol 1991; 11:237-241
5.
Albucher RC, Curtis GC: Adderall for obsessive-compulsive disorder (letter). Am J Psychiatry 2001; 158:818-819
6.
Owley T, Owley S, Leventhal B, Cook EH Jr: Case series: Adderall(R) augmentation of serotonin reuptake inhibitors in childhood-onset obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 2002; 12:165-171
7.
Insel TR, Hamilton JA, Guttmacher LB, Murphy DL: D-Amphetamine in obsessive-compulsive disorder. Psychopharmacology (Berl) 1983; 80:231-235

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 183
PubMed: 12505824

History

Published online: 1 January 2003
Published in print: January 2003

Authors

Affiliations

JAMES B. WOOLLEY, M.R.C.Psych., M.R.C.P.
ISOBEL HEYMAN, Ph.D., M.R.C.Psych.
London, U.K.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share